文献速递骨软组织肉瘤与黑色素瘤

BRAF V600突变转移性黑色素瘤的预后亚组模型:4项随机临床试验汇总分析

Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
PubMed 文献 · JAMA Oncol · 2018-01-01

该回顾性探索性递归分区分析汇总BRIM-2、BRIM-3、BRIM-7和coBRIM研究1365例BRAF V600突变转移性黑色素瘤患者,识别出基于基线LDH、ECOG PS、肝转移和靶病灶SLD的预后亚组,并评估不同治疗下的生存差异。

要点

  • 基线LDH、ECOG PS、肝转移和SLD是PFS的显著预后因素。
  • LDH正常且无肝转移者中位OS最长(22.7个月)。
  • 最有利亚组中,cobimetinib联合vemurafenib的3年OS率高于单药。

核心结论

  • 基线LDH、ECOG PS、疾病负荷和基因特征是BRAF V600突变转移性黑色素瘤生存结局的关键决定因素。
  • 结果与coBRIM研究中cobimetinib联合vemurafenib优于vemurafenib单药的生存获益一致。

研究设计与样本

  • 回顾性探索性递归分区分析(RPA),汇总BRIM-2、BRIM-3、BRIM-7和coBRIM研究数据。
  • 纳入1365例患者(783例男性,57.4%),其中310例接受cobimetinib联合vemurafenib,717例接受vemurafenib单药,338例接受达卡巴嗪。
  • 中位随访14.1个月(四分位距6.3-28.3个月)。

主要发现

  • PFS最长见于LDH≤2×ULN、ECOG PS 0且SLD≤44 mm者(11.1个月,95%CI 7.0-18.4),最短见于LDH>2×ULN者(3.5个月,95%CI 3.0-3.8)。
  • OS最长见于基线LDH正常且无肝转移者(22.7个月,95%CI 20.3-27.2)。
  • OS最长见于LDH正常且SLD≤45 mm者(27.2个月,95%CI 22.1-32.1),最短见于LDH>2×ULN者(6.0个月,95%CI 5.3-6.8)。
  • 最有利亚组(LDH正常且SLD≤45 mm)3年OS率:cobimetinib联合vemurafenib组53.3%(95%CI 39.5%-67.1%),vemurafenib组35.6%(95%CI 27.4%-43.8%),达卡巴嗪组35.6%(95%CI 24.8%-46.4%)。
  • 在LDH正常且有基因表达数据者中,基因特征为PFS显著预后因素,免疫特征和细胞周期特征的3年PFS率分别为21.9%(95%CI 15.4%-28.4%)和8.8%(95%CI 3.6%-14.1%)。

关键数值与推荐

  • 预后不良因素包括基线LDH>2×ULN、ECOG PS≥1、存在肝转移和较大SLD。
  • LDH正常且SLD≤45 mm为最有利亚组。

临床怎么用

  • 可通过基线LDH、ECOG PS、肝转移和SLD对BRAF V600突变转移性黑色素瘤患者进行预后分层。
  • 最有利亚组接受cobimetinib联合vemurafenib的3年OS率高于单药治疗。

局限性

  • 回顾性探索性分析,结果需前瞻性验证。
  • 基因表达数据仅部分患者可用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Prognostic models may provide insight into clinical trial results and inform the clinical management of patients with BRAF V600-mutated metastatic melanoma. OBJECTIVE: To identify subgroups with distinct survival outcomes based on clinical and genomic characteristics and to assess survival in identified prognostic subgroups across cohorts treated with dacarbazine, vemurafenib, or cobimetinib plus vemurafenib. DESIGN, SETTING, AND PARTICIPANTS: This retrospective and exploratory recursive partitioning analysis (RPA) modeled associations between prespecified covariates and survival outcomes using pooled data from the BRIM-2, BRIM-3, BRIM-7, and coBRIM studies. INTERVENTIONS: Dacarbazine, vemurafenib, or cobimetinib plus vemurafenib. MAIN OUTCOMES AND MEASURES: Progression-free survival (PFS) and overall survival (OS), estimated using the Kaplan-Meier method. RESULTS: The RPA included 1365 patients (783 men; 57.4%). Of these, 1032 (75.6%) were older than 65 years; 310 received cobimetinib plus vemurafenib; 717, vemurafenib alone; and 338, dacarbazine. Median follow-up was 14.1 months (interquartile range, 6.3-28.3 months). In the RPA that included all patients, baseline lactate dehydrogenase (LDH) level, Eastern Cooperative Oncology Group performance status (ECOG PS), presence or absence of liver metastases, and baseline sum of longest diameters of target lesions (SLDs) were significant prognostic factors for PFS: Median PFS was longest in patients with lower LDH (≤2 × upper limit of normal [ULN]), ECOG PS 0, and shorter SLD (≤44 mm) (11.1 months; 95% CI, 7.0-18.4 months), and shortest in those with elevated LDH (>2 × ULN) (3.5 months; 95% CI, 3.0-3.8 months). The subgroup with normal baseline LDH and no liver metastases had the longest median OS (22.7 months; 95% CI, 20.3-27.2 months). Similar PFS trends were observed when these prognostic subgroups were applied to the cobimetinib plus vemurafenib, vemurafenib alone, and dacarbazine cohorts. Baseline LDH, ECOG PS, and SLD were significant prognostic factors for OS: Median OS was longest in patients with normal LDH and shorter SLD (≤45 mm) (27.2 months; 95% CI, 22.1-32.1 months) and shortest in those with elevated LDH (>2 × ULN) (6.0 months; 95% CI, 5.3-6.8 months). Among patients in the most favorable subgroup (normal LDH and SLD ≤45 mm), 3-year OS rates were 53.3% (95% CI, 39.5%-67.1%) in the cobimetinib plus vemurafenib cohort, 35.6% (95% CI, 27.4%-43.8%) in the vemurafenib cohort, and 35.6% (95% CI, 24.8%-46.4%) in the dacarbazine cohort. Among patients with available gene expression data, RPA identified gene signature as a significant prognostic factor for PFS in those with normal LDH; 3-year PFS rates were 21.9%, (95% CI, 15.4%-28.4%) and 8.8% (95% CI, 3.6%-14.1%) in immune and cell cycle signature, respectively. The RPA for OS did not identify gene signature as a significant factor. CONCLUSIONS AND RELEVANCE: Baseline LDH, ECOG PS, disease burden, and gene signature appear to be key determinants of survival outcomes in patients with BRAF V600-mutated metastatic melanoma treated with BRAF and/or MEK inhibitors. These results are consistent with survival benefits of cobimetinib plus vemurafenib over vemurafenib alone observed in the coBRIM study.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Hauschild A, Larkin J, Ribas A, et al. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials. JAMA Oncol. 2018. PMID: 30073321. doi:10.1001/jamaoncol.2018.2668

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。